Key result
LOXL2 silencing inhibits ox-LDL-induced endothelial inflammation, ROS production, and EndMT progression.
Why the study?
Does LOXL2 silencing prevent ox-LDL-induced endothelial dysfunction and EndMT in HUVECs?
Does LOXL2 silencing prevent ox-LDL-induced endothelial dysfunction and EndMT in HUVECs?
Answers are grounded in this paper and cite their sources.
LOXL2 silencing protects against ox-LDL-induced endothelial cell dysfunction, likely by inhibiting the endothelial-to-mesenchymal transition (EndMT) pathway.
INTRODUCTION: Our research aimed to investigate the potential role and mechanism of lysyl oxidase (LOX)-like 2 (LOXL2) in atherosclerosis (AS) by using the human umbilical vein endothelial cells (HUVECs) stimulated by oxidized low-density lipoprotein (ox-LDL). METHODS: HUVECs were treated with ox-LDL at different concentrations (0, 10, 25, 50, and 100 μg/mL) and incubated for 24 h. The transfection efficacy of siLOXL2 was investigated by Western blot and real-time quantitative polymerase chain reaction (RT-qPCR). Cell migration, intracellular ROS measurement, oxidative stress, enzyme-linked immunosorbent assay, and adhesion assays were carried out to examine the ox-LDL-induced HUVECs injury. RT-qPCR and Western blot were used to determine gene and protein expression levels. RESULTS: LOXL2 protein expression increased in ox-LDL-induced endothelial cells (ECs). ox-LDL + siLOXL2 significantly inhibited the migration ability of HUVECs and reduced the expression of vascular endothelial growth factor A (VEGFA) and matrix metalloproteinase 9 gene expressions (all, p < 0.05). The ox-LDL + siLOXL2 significantly reduced intracellular ROS production and inhibited the expression of Malondialdehyde, whereas it markedly enhanced superoxide dismutase and catalase (all, p < 0.05). Supernatant levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were significantly attenuated by the ox-LDL + siLOXL2 treatment (all, p < 0.05). ox-LDL + siLOXL2 markedly suppressed the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 (all, p < 0.05). ox-LDL + siLOXL2 treatment remarkably reduced the expression of α-smooth muscle actin and vimentin, while increased CD31 and von Willebrand factor gene expression (all, p < 0.05). CONCLUSION: LOXL2 silencing is protected against ox-LDL-induced EC dysfunction, and the mechanism may be related to the inhibition of the EndMT pathway.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2024) studied Atherosclerosis (in vitro model). siLOXL2 (LOXL2 silencing) vs. ox-LDL alone was evaluated on Cell migration, ROS production, inflammatory cytokines, adhesion molecules, and EndMT markers (p=<0.05). LOXL2 silencing inhibited ox-LDL-induced endothelial cell migration, ROS production, inflammatory cytokine expression, and EndMT pathway markers.
Synapse has enriched 10 related papers. Consider them for comparative context: